Clinical Trial Update: Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating avelumab in combination with gemcitabine for advanced, metastatic leiomyosarcoma as second-line therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leiomyosarcoma

Drugs mentioned

• Avelumab (avelumab)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Gachon University Gil Medical Center | Conditions: Leiomyosarcoma Metastatic | Phase 2 | Status: UNKNOWN